Fund moves
8.2%Stake
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
LEXX · NASDAQ · Pharmaceutical Preparations
Lexaria Bioscience (LEXX) · oqro.io/stocks/LEXX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$4.49+0.21 (+4.91%)
Close of Nov 19, 2026, vs Nov 18 · end-of-day, not a live quote
−72.8% (−$12.01) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $16.50 on Nov 19, 2025 to $4.49 on Nov 19, 2026 (−72.8%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Kelowna, A1.
Last 12 months
−72.8%
Market value
$111M
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 217K shares sold short (0.9% of shares outstanding), −15.0% vs the previous count, 5.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$0
−100.0% vs the same quarter a year earlier
Free cash flow, last 12 months
−$7.47M
This quarter −$1.64M, a year earlier −$3.58M
Net debt
—
Debt —, cash $3.5M, at May 31, 2026
Net income, last 12 months
−$7.73M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Revenue, fiscal 2025
$706K
+52.0% vs the year before
Net income, fiscal 2025
−$11.9M
A loss for the year
Shares outstanding
24.8M
As of Jul 13, 2026
Fund moves
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Insider buying
Traded Jul 29, 2025 · filed 1 day later
Since the trade −66.3% · S&P 500 +12.7% · to Nov 19
The CEO of Lexaria Bioscience paid $14K out of pocket for Lexaria Bioscience shares. 4 other people at Lexaria Bioscience bought some too, in the same month. It was the first purchase in 7 months.
Insider buying
Traded Jul 29, 2025 · filed 1 day later
Since the trade −66.3% · S&P 500 +12.7% · to Nov 19
A Lexaria Bioscience director paid $4.5K out of pocket for Lexaria Bioscience shares. 4 other people at Lexaria Bioscience bought some too, in the same month. Shares held went up 38% with this purchase.
Traded Jul 29 – Jul 30, 2025 · largest single transaction ~$14K
Jul 29, 2025~$14K · 16K sh @ $0.9215
DetailsOfficial recordJul 30, 2025~$11K · 12K sh @ $0.9131
DetailsOfficial recordPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
No open-market purchase by an insider of Lexaria Bioscience was filed in the last 90 days. The latest on record was on Jul 30, 2025.
Since 2006, Lexaria Bioscience insiders reported 652 open-market purchases and 5 sales on Forms 4 and 5, with purchases in 14 different years, most recently 2025.
No open-market sale by an insider of Lexaria Bioscience (LEXX) was filed with the SEC in the last 90 days.
No trade in Lexaria Bioscience (LEXX) was disclosed by a member of Congress in the last 12 months.
Lexaria Bioscience's next results are expected on Nov 26, 2026, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
Latest annual report filed Nov 28, 2025, compared with the one filed Nov 26, 2024. Read the filing
We are not party to any material, pending or existing legal proceedings against our Company or its subsidiaries nor are we involved as a plaintiff in any other material proceeding or pending litigation. There are no other proceedings in which any of our directors, executive officers, or affiliates, or any registered or beneficial stockholder, is an adverse party or has a material interest adverse to Lexaria or any of its subsidiaries.
Source: SEC EDGAR, Form 10-K filed Nov 28, 2025. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
Off-exchange trading: 41.4% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (7.9% on ATS, 33.5% with other brokers), above its 11-week average of 34.9%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (23.1%), SIGMA X2 (16.3%), IBKR ATS (14.8%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Insiders of Lexaria Bioscience reported 652 open-market purchases and 5 sales since 2006; purchases in 14 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $49K6×6 trades | — |
| 2024 | $123K3×3 trades | $10K1×1 trade |
| 2023 | $4.3K1×1 trade | — |
| 2022 | $79K3×3 trades | — |
| 2020 | $40K10×10 trades | — |
| 2018 | — | $95K3×3 trades |
| 2016 | $92K50×50 trades | — |
| 2015 | $803K313×313 trades | — |
| 2014 | $152K32×32 trades | — |
| 2012 | $5.7K6×6 trades | — |
| 2011 | $223K74×74 trades | — |
| 2010 | $157K79×79 trades | $2451×1 trade |
| 2009 | $162K39×39 trades | — |
| 2008 | $77K35×35 trades | — |
| 2006 | $583K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Against the S&P 500 over the year
Since Nov 18, 2025, LEXX is down 71.5% and the index fund is up 8.5%: 80 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much LEXX moves
Beta 0.7 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Fiscal year Sep 1, 2024 to Aug 31, 2025, from the annual report filed Nov 28, 2025. Read the filing
+52% on the year before ($458K)
+84% on the year before ($5.4K)
$900 the year before
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 4,000 words.
Lexaria’s DehydraTECH patented technology improves the delivery of bioactive compounds while promoting healthy ingestion methods, lowers overall dosing, and is highly effective in active molecule delivery available in a range of formats from oral ingestible to oral buccal/sublingual products. DehydraTECH substantially improves the rapidity and quantity of API transport to the blood plasma using the body’s natural process for distributing fatty acids via the oral route. This technology extends across many categories beyond the primary pharmaceutical focus of the Company from foods and beverages to cosmetic products and nutraceuticals. Lexaria is advancing several R&D activities in both preclinical and planned future clinical programs.
Source: SEC EDGAR, Form 10-K filed Nov 28, 2025. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Last results
—
Next results, expected
Nov 26, 2026
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Lexaria Bioscience's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Lexaria Bioscience's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Notice of delisting or failure to meet listing rules
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.